Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q4 FY24 Earnings Presentation
21 slides from Thyrocare Technologies's earnings presentation, May 14, 2024
Slide 1: Thyrocare: Tests you can trust
0 Thyrocare Tests you can trust May 14, 2024 I The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Investors Pre
Slide 2: Presentation: Q4 and Annual Results FY24
3 Thyrocare Tests you can trust Presentation Q4 and Annual Results FY24
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company's performance may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied.Impo
Slide 4: Agenda
Agenda 01 FY24 - A look back 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 2 02
Slide 5: FY24 - A look back
FY24 - A look back 7982 30 Labs ~ Thyrocare 18% (25 NABL Accreditated) 3 Yrs Non-COVID Revenue CAGR Tests you can t r ust Financial Parameters Operations Quality >Consolidated revenue for FY24 is Rs. 572 Cr ~ p? Active Franchisees 7,900+ (+8% YoY) <I .... Samples processed in NABL Labs 94% (+9 pps Y
Slide 6: New initiatives: Product launches and Awareness through KOLs
New initiatives: Product launches and Awareness through KOLs Product launches Awareness through KOLs Jaanch Jaan~ For o closer look ot your health with Troponin I dtMl®'tMttttt> Investigative doctor curated packages Her Check 360 UEG REI-: CA RE CH ECK f-er Ew rr l'lttt,w O( HE RLLFE -~ For heart at
Slide 7: Agenda
Agenda 01 FY24 - A look back 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 5 05
Slide 8: Quarter health-check (Q4FY24 vs Q4FY23)
Quarter health-check (Q4FY24 (Q4FY24vs vsQ4FY23) Q4FY23) YoY Core 8 8 YoY TTL Consolidated +5% +14% Business YoY Core Business +18% Revenue ## Revenue Revenue* 8 8 Radiology** YoY Pathology +5% +11% YoY Radiology +9% +15% Revenue** +16% Revenue# e e YoY Normalized +3% +4% Normalized 26% 27% EBIDTA##
Slide 9: Annual health-check (FY24 vs FY23)
Annual health-check (FY24 Annual (FY24 vs vs FY23) FY23) YoY Core t 8 +5% +9% Business YoY Core Business +16% YoY TTL Consolidated 0 +gofc Revenue ## Revenue 0 Revenue* ~ 8 8 Radiology** YoY Pathology +5% +8% YoY Radiology +9% +18% +10% Revenue** Revenue# e e YoY Normalized +3% +8% Normalized 26% 28
Slide 10: Y-o-Y growth in overall business and Normalized EBITDA
5% Y-o-Y growth in overall business; 14% 14% 3% 4%4% Y-o-Y growth in Normalized EBITDA Consolidated Revenue (INR Cr) Normalized EBITDA (INR Cr) +14% +4% : ·· - ··- .. -·· - .. - .. - +14% - .. - .. - .. - ··- ··- .. ~ +4% -· · -·· -··- ·· - ·· , . +5% ; +3% ., 42.5 42.1 40.6 41.7 42.5 ~ 148.0 41.7 1
Slide 11: Franchise revenue grew 13% Y-o-Y; Partnerships grew 40%
13% Y-o-Y; Partnerships (excluding API & B2G) grew by 40% Franchise revenue grew by 13% 40% Y-o-Y Pathology Revenue (Rs Cr) Pathology Workload (Lakhs) Pathology Revenue (Rs Cr) YoY Growth Pathology Workload (Lakhs) 42.2 86.6 83.5 39.7 42.2 40.1 38.8 39.7 40.1 79.7 86.6 +13% 3 38.8 36.6 73.8 76.0 83.
Slide 12: Top line revenue growth moving towards pre covid levels
Top line revenue growth moving towards pre covid levels : Franchise base at >2x over last Top3line years growth now higher than pre-COVID levels : Franchise base at >2x over last 3 years 600 561.5 524.3 YoY Non-Covid Growth 486.5 500 474.3 Non-Covid FY24 vs Growth FY21 - +18% (CAGR) 524.0 400 486.5
Slide 13: Agenda
Agenda 01 FY24 -–AA look FY24 Lookback Back 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 11 11
Slide 14: Income statement - TTL Standalone
Income statement - TTL Standalone Quarter Annual Pathology revenue grew by 10% INR crore Q4FY24 Q4FY23 YoY FY24 FY23 YoY YoY, while the Franchise grew by Revenue from operations 141.2 124.8 13% 524.0 486.5 8% 14%; Partnerships (excluding API & Cost of materials consumed/sold (44.1) (39.6) (157.6) (1
Slide 15: Income statement - NHL Standalone (Excluding Pulse Hitech)
Income statement - NHL Standalone (Excluding Pulse Hitech) Quarter Annual ,.. -... l NHL Revenue increased 7% YoY ' INR crore Q4FY24 Q4FY23 YoY FY24 FY23 YoY 11.2 11.1 1% 43.2 40.2 7% on account of increase in FDG Revenue from operations Cost of materials consumed/sold (2.5) (2.1) (8.7) (6.9) sales
Slide 16: Income statement - TTL Consolidated
Income statement - TTL Consolidated Quarter Annual ( --------------------------------------~ \ Revenue from operations INR crore Q4FY24 Q4FY23 YoY FY24 FY23 YoY Revenue from operations 154.2 135.9 14% 571.9 526.7 9% includes Pulse Hitech and Think Cost of materials consumed/sold (46.6) (41.8) (166.7
Slide 17: Agenda
Agenda 01 FY24 - A look back 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 15 15
Slide 18: Vision & Mission
Vision & Mission Global in our reach excellence in our experience Vision To ensure everyone has access to quality & affordable diagnostics Mission 16 16
Slide 19: Our strategy remains to be a service provider with an affordable value driven model
Our strategy remains to be a 828 service provider with an affordable value driven model based on scale efficiencies 0 Thyrocare Tests you can trust ~ - - - - - - - - - 'I I .____- - - - ~ ~ l Franchise Partnership +B2G > Mom & Pop collection centers >Online diagnostics aggregators > Local labs > Hea
Slide 20: Going forward - Key pillars of growth
Going forward - Key pillars of growth Public & Private I nternationa I Franchise Partnerships Expansion > Going deeper into India with > Focus on TB and Infectious > Exploring to take our B2B focused test menu Disease a long with large model to emerging markets to screening programs run by deliver a
Slide 21: Thank You
,0 Thyrocare Tests you can trust For Any queries, please reach out to investor_relations@thyrocare .com Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company's activities. The Company assumes no responsibility ta publ
Thyrocare Technologies — Q4 FY24 Earnings Presentation on 6ix